{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"39","value":"17"},{"groupId":"OG001","lowerLimit":"13","upperLimit":"21","value":"16"},{"groupId":"OG002","lowerLimit":"8","upperLimit":"36","value":"15"},{"groupId":"OG003","lowerLimit":"14","upperLimit":"17","value":"14"},{"groupId":"OG004","lowerLimit":"11","upperLimit":"28","value":"18"},{"groupId":"OG005","lowerLimit":"16","upperLimit":"16","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"description":"The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is \\> 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.\n\ncyclophosphamide\n\ncyclosporine\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"OG000","title":"Regimen I"},{"description":"Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.\n\nbusulfan\n\ncyclophosphamide\n\ncyclosporine\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG001","title":"Regimen II"},{"description":"Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.\n\ncyclosporine\n\netoposide\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"OG002","title":"Regimen III"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.\n\ncyclosporine\n\nfludarabine phosphate\n\nmelphalan\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG003","title":"Regimen IV"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.\n\ncyclosporine\n\nfludarabine phosphate\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"OG004","title":"Regimen V"},{"description":"Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.\n\nbusulfan\n\ncyclosporine\n\nfludarabine phosphate\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"OG005","title":"Regimen VI"}],"paramType":"MEDIAN","populationDescription":"Some patients had engraftment failure and some had missing data. Therefore, the overall number of participants analyzed in each regimen is less than the overall number in the Participant Flow module.","reportingStatus":"POSTED","timeFrame":"Up to 180 days post transplant","title":"Neutrophil Engraftment - The Days Till ANC Recovery","type":"PRIMARY","unitOfMeasure":"days"}